At a glance
ClinicalIndex Comparison RecordPhase 2Active· 24 enrolled
Drug / intervention
ACP-196drug
Likely dose
ACP-196 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
In Brief
A Phase 2 clinical trial evaluating ACP-196 for Glioblastoma Multiforme. Active but no longer recruiting, targeting 24 participants across 7 sites.
Detailed Summary
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme
CountriesUnited States
Collaborators--
Timeline
Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJan 2016
Primary CompletionJun 2020
Study CompletionApr 2026
TodayJul 2026
First PostedOct 27, 2015
Enrollment StartJan 25, 2016
Primary CompletionJun 26, 2020
Study CompletionApr 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.7 years ago
Interventions
ACP-196drug
Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).